The Food and Drug Administration (FDA) has approved Pembrolizumab (an anti-PD-1 inhibitor) for use in unresectable melanoma, non-small-cell lung cancer, recurrent or metastatic head and neck squamous cell cancers, classical Hodgkin lymphoma and in PD-L1-positive cervical cancer. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.